Eric B. Suhler

8.1k total citations · 1 hit paper
143 papers, 4.9k citations indexed

About

Eric B. Suhler is a scholar working on Ophthalmology, Rheumatology and Epidemiology. According to data from OpenAlex, Eric B. Suhler has authored 143 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Ophthalmology, 43 papers in Rheumatology and 16 papers in Epidemiology. Recurrent topics in Eric B. Suhler's work include Ocular Diseases and Behçet’s Syndrome (125 papers), Retinal and Optic Conditions (71 papers) and Systemic Lupus Erythematosus Research (33 papers). Eric B. Suhler is often cited by papers focused on Ocular Diseases and Behçet’s Syndrome (125 papers), Retinal and Optic Conditions (71 papers) and Systemic Lupus Erythematosus Research (33 papers). Eric B. Suhler collaborates with scholars based in United States, Australia and India. Eric B. Suhler's co-authors include James T. Rosenbaum, Jennifer E. Thorne, Robert B. Nussenblatt, Grace A. Levy-Clarke, Douglas A. Jabs, John H. Kempen, C. Stephen Foster, R. Oktay Kaçmaz, Ebenezer Daniel and Sapna Gangaputra and has published in prestigious journals such as New England Journal of Medicine, JAMA and Ophthalmology.

In The Last Decade

Eric B. Suhler

132 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab in Patients with Active Noninfectious Uveitis

2016 418 citations Glenn J. Jaffe, Andrew D. Dick et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric B. Suhler United States	40	4.1k	1.6k	872	479	477	143	4.9k
İlknur Tuğal-Tutkun Türkiye	38	4.0k 1.0×	1.3k 0.8×	788 0.9×	400 0.8×	341 0.7×	133	4.6k
Manfred Zierhut Germany	34	3.6k 0.9×	1.4k 0.8×	661 0.8×	443 0.9×	484 1.0×	227	4.9k
Phuc LeHoang France	42	4.1k 1.0×	768 0.5×	552 0.6×	167 0.3×	1.0k 2.2×	201	5.7k
Dongsik Bang South Korea	29	1.9k 0.5×	1.1k 0.7×	853 1.0×	375 0.8×	478 1.0×	167	3.3k
Erkan Alpsoy Türkiye	34	1.7k 0.4×	1.4k 0.9×	810 0.9×	406 0.8×	637 1.3×	132	3.9k
Annabelle A. Okada Japan	36	3.6k 0.9×	521 0.3×	284 0.3×	146 0.3×	412 0.9×	144	4.3k
Debra A. Goldstein United States	31	2.4k 0.6×	469 0.3×	279 0.3×	127 0.3×	327 0.7×	163	3.1k
Joke H. de Boer Netherlands	30	2.0k 0.5×	556 0.3×	119 0.1×	481 1.0×	624 1.3×	101	2.5k
C. Stephen Foster United States	31	1.7k 0.4×	711 0.4×	189 0.2×	214 0.4×	386 0.8×	84	3.0k
James S. Louie United States	28	681 0.2×	1.1k 0.7×	259 0.3×	268 0.6×	424 0.9×	72	2.8k

Countries citing papers authored by Eric B. Suhler

Since Specialization

Citations

This map shows the geographic impact of Eric B. Suhler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric B. Suhler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric B. Suhler more than expected).

Fields of papers citing papers by Eric B. Suhler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric B. Suhler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric B. Suhler. The network helps show where Eric B. Suhler may publish in the future.

Co-authorship network of co-authors of Eric B. Suhler

This figure shows the co-authorship network connecting the top 25 collaborators of Eric B. Suhler. A scholar is included among the top collaborators of Eric B. Suhler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric B. Suhler. Eric B. Suhler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Watkins, Timothy R., Quan Dong Nguyen, David K. Scales, et al.. (2024). Filgotinib in Active Noninfectious Uveitis. JAMA Ophthalmology. 142(9). 789–789. 7 indexed citations

Huang, Lingling, Paul Yang, Christina J. Flaxel, Eric B. Suhler, & Phoebe Lin. (2024). SUCCESSFUL TREATMENT OF CANCER-ASSOCIATED RETINOPATHY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOLLOWED BY A 0.18-MG FLUOCINOLONE IMPLANT WITHOUT SYSTEMIC IMMUNOSUPPRESSION. Retinal Cases & Brief Reports. 19(2). 214–220. 2 indexed citations

Miller, D. Claire, SR Rathinam, John A. Gonzales, et al.. (2023). Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Journal of Ophthalmic Inflammation and Infection. 13(1). 29–29. 1 indexed citations

Pasadhika, Sirichai, Akshay S. Thomas, Bryn M. Burkholder, et al.. (2023). Characterization of autoimmune eye disease in association with Down’s syndrome. Eye. 38(2). 386–392. 1 indexed citations

Bui, Anh, Christina Kong, Sivakumar R. Rathinam, et al.. (2022). Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil. Ophthalmology. 129(6). 721–723. 3 indexed citations

Kempen, John H., Craig Newcomb, C. Stephen Foster, et al.. (2019). Risk of Overall and Cancer Mortality After Immunosuppression of Patients with Non-infectious Ocular Inflammatory Diseases.. Investigative Ophthalmology & Visual Science. 60(9). 3854–3854. 1 indexed citations

Suhler, Eric B.. (2018). Safety and Efficacy of an intravitreal 0.18 mg fluocinolone acetonide insert (FAi) for the treatment of non-infectious posterior segment uveitis (NIPU) – pooled results of two phase 3 trials. Investigative Ophthalmology & Visual Science. 59(9). 5952–5952. 1 indexed citations

Jaffe, Glenn J., Andrew D. Dick, Antoine P. Brézin, et al.. (2016). Adalimumab in Patients with Active Noninfectious Uveitis. New England Journal of Medicine. 375(10). 932–943. 418 indexed citations breakdown →

Jia, Yali, Liang Liu, Neal Palejwala, et al.. (2015). Assessment of Macular Circulation in Patients With Retinal Vasculitis using OCT Angiography. Investigative Ophthalmology & Visual Science. 56(7). 3359–3359. 1 indexed citations

10.

Suhler, Eric B., Tracy R. Giles, Phoebe Lin, Amde Selassie Shifera, & James T. Rosenbaum. (2015). An Open-Label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis-Associated Uveitis: Preliminary Results. Investigative Ophthalmology & Visual Science. 56(7). 860–860. 1 indexed citations

11.

Kothari, Srishti, Maxwell Pistilli, C. Stephen Foster, et al.. (2014). Risk of Elevated Intraocular Pressure (IOP) in Pediatric Non-infectious Uveitis. Investigative Ophthalmology & Visual Science. 55(13). 844–844.

12.

Daniel, Ebenezer, Maxwell Pistilli, H. Nida Sen, et al.. (2014). Incidence and Risk Factors for Ocular Hypertension in Adults with Non-infectious Uveitis. Investigative Ophthalmology & Visual Science. 55(13). 6031–6031. 1 indexed citations

13.

Suhler, Eric B., Tracy R. Giles, Teresa L. Liesegang, et al.. (2013). A Phase I/II Dose-Ranging, Randomized Clinical Trial of Abatacept (Orencia) in the Treatment of Refractory Non-Infectious Uveitis: Preliminary Results. Investigative Ophthalmology & Visual Science. 54(15). 5190–5190. 3 indexed citations

14.

Beardsley, Robert S., et al.. (2013). Optovue OCT as an Imaging Modality for Scleral Thickness. Investigative Ophthalmology & Visual Science. 54(15). 4868–4868.

15.

Suhler, Eric B., et al.. (2012). Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. Journal of Ophthalmic Inflammation and Infection. 2(4). 177–182. 5 indexed citations

16.

Kopani, Kamden R., et al.. (2011). Intravitreal Triamcinolone Acetonide in the Treatment of Uveitic Cystoid Macular Edema: A Comparison of 1mg, 2mg and 4mg doses. Investigative Ophthalmology & Visual Science. 52(14). 4265–4265. 1 indexed citations

17.

Butler, Nicholas J., Lyndell L. Lim, Tracy R. Giles, et al.. (2011). Rituximab In The Treatment Of Refractory Scleritis And Non-infectious Orbital Inflammation: 24 Week Outcomes From A Phase I/II Prospective, Randomized Study. Investigative Ophthalmology & Visual Science. 52(14). 4251–4251. 1 indexed citations

18.

Mackensen, Friederike, Jing Xie, Chong Chyn Chua, et al.. (2009). In Vivo Laser Confocal Microscopy of Keratic Precipitates Is a Useful Tool in Differencing Specific Uveitis Diagnosis as Well As Active From Inactive Uveitis. Investigative Ophthalmology & Visual Science. 50(13). 1525–1525. 1 indexed citations

19.

Suhler, Eric B., Justine R. Smith, Andreas K. Lauer, et al.. (2004). A Prospective Trial of Infliximab Therapy for Patients with Refractory Uveitis: Interim Analysis of Safety and Efficacy Outcomes. Investigative Ophthalmology & Visual Science. 45(13). 3370–3370. 1 indexed citations

20.

Suhler, Eric B., et al.. (2003). A Prospective Trial of Infliximab Therapy for Patients with Refractory Uveitis: Preliminary Results. Investigative Ophthalmology & Visual Science. 44(13). 2011–2011. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact